Economic Burden of Hypercholesterolemia in the Russian Federation

被引:6
|
作者
Kontsevaya, Anna V. [1 ]
Balanova, Yulia A. [2 ]
Imaeva, Asia E. [3 ]
Khudyakov, Mihail B. [2 ]
Karpov, Oleg I. [4 ]
Drapkina, Oksana M. [5 ]
机构
[1] Natl Med Res Ctr Prevent Med, Sci & Analyt Work, Petroverigsky Per 10, Moscow 101990, Russia
[2] Natl Med Res Ctr Prevent Med, Lab Econ Anal Epidemiol Res & Prevent Technol, Dept Epidemiol Chron Noncommunicable Dis, Petroverigsky Per 10, Moscow 101990, Russia
[3] Natl Med Res Ctr Prevent Med, Dept Epidemiol Chron Noncommunicable Dis, Petroverigsky Per 10, Moscow 101990, Russia
[4] Publ Co Sanofi Russia, Hlth Econ & Outcomes Res Grp, Tverskaya Ul 22, Moscow 125009, Russia
[5] Natl Med Res Ctr Prevent Med, Petroverigsky Per 10, Moscow 101990, Russia
关键词
hypercholesterolemia; cardio-vascular diseases; economic burden; health care expenditures;
D O I
10.20996/1819-6446-2018-14-3-393-401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The prevalence of hypercholesterolemia (HCE) is quite high in the Russian Federation (RF), and it is associated with clinical consequences and with potential economic impact. Impact includes not only cost of its correction, but also the cost of treatment of diseases and complications, as well as the deficiency of the gross domestic product (GDP). Aim. Evaluation of economic impact due to HCE in the Russian population, including direct expenditures of the Health Care System as well as nondirect impact in common economy. Material and methods. Prevalence of HCE in the RF was identified based on local published studies. Local statistical data (2016) on cardio-vascular diseases (CVDs), including Ischemic Heart Disease (IHD), Myocardial Infarction and cerebral-vascular disease were included in the analysis. Population Attributive Risk (PAR) of HCE in CVDs has been extrapolated on all Russian population. Official statistics, parameters of Govern Guarantees Program of Free Medical Aid were used for modelling of direct and non-direct components of economic impact. Total amount of premature deaths with calculation of years of potential life lost until life expectation at 72 years was calculated. Economic impact due to premature CVDs mortality in economic activity age with consideration on ratio of employment have included GDP lost. Calculation of GDP lost also included monetary impact based on number of disability CVDs patients multiplied on GDP per capita in disability group. Results. Visits to policlinics of patients with CVDs and HCE had a first place among all calls for medical aid. In the same time, hospitalization required in higher expenditures (outpatients cost treatment expenditures were 2.43 billion RUR, in-patients treatment -18.21 billion RUR). IHD with HCE was most expensive for direct expenditures in comparison with other CVD groups: more than 28.9 billion RUR per year, and with direct non-medical expenditures of 29.3 billion RUR in total. Years of potential life lost in economic active age were one million in total, 1.29 trillion RUR per year mostly due to indirect expenditures due to premature deaths in economy activity age (99% of impact). Total Economic impact due to HCE in the Russian population for all HCE are estimated as 1.295 trillion RUR. Conclusion. Total economic impact due to HCE in the RF is 1.5% of GDP (2016), 1.295 trillion RUR. Direct expenditures included Health Care System expenses; disability covering had 2.3% only. Main part of impact is economic lost due to premature mortality and decrease of labor productivity. HCE patients control at target levels with help of healthy lifestyle and adequate pharmaceutical therapy can decrease economic impact.
引用
收藏
页码:393 / 401
页数:9
相关论文
共 50 条
  • [1] Economic Burden of Hypertension in the Russian Federation
    Balanova, Yulia A.
    Kontsevaya, Anna, V
    Myrzamatova, Azalia O.
    Mukaneeva, Dinara K.
    Khudyakov, Mihail B.
    Drapkina, Oxana M.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (03) : 415 - 423
  • [2] ECONOMIC BURDEN OF CARDIOVASCULAR DISEASES IN RUSSIAN FEDERATION
    Kontsevaya, A.
    Kalinina, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A368 - A368
  • [3] Economic burden of cardiovascular disease in the Russian Federation
    Oganov, R. G.
    Kontsevaya, A. V.
    Kalinina, A. M.
    [J]. CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (04): : 4 - 9
  • [4] ECONOMIC BURDEN OF POMPE DISEASE IN THE RUSSIAN FEDERATION
    Kolbin, A.
    Velum, I
    Balykina, Y.
    Proskurin, M.
    Karpov, O.
    [J]. VALUE IN HEALTH, 2019, 22 : S340 - S340
  • [5] Economic burden of cardiovascular diseases in Russian Federation
    Kontsevaya, A.
    Kalinina, A.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 807 - 807
  • [6] Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016
    Kontsevaya, Anna V.
    Drapkina, Oxana M.
    Balanova, Yulia A.
    Imaeva, Asia E.
    Suvorova, Evgenia I.
    Khudyakov, Mihail B.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2018, 14 (02) : 156 - 166
  • [7] The economic burden of chronic thromboembolic pulmonary hypertension in Russian Federation
    Chazova, I. E.
    Martynyuk, T., V
    Valieva, Z. S.
    Nakonechnikov, S. N.
    Nedogoda, S., V
    Salasyuk, A. S.
    Taran, I. N.
    Gratsianskaya, S. E.
    [J]. TERAPEVTICHESKII ARKHIV, 2018, 90 (09): : 101 - 109
  • [8] EXCESSIVE SALT INTAKE: PREVALENCE AND ECONOMIC BURDEN IN THE RUSSIAN FEDERATION
    Balanova, Yulia
    Shalnova, S.
    Imaeva, A.
    Kontsevaya, A.
    Myrzamatova, A.
    Mukaneeva, D.
    Khudyakov, M.
    [J]. JOURNAL OF HYPERTENSION, 2021, 39 : E170 - E170
  • [9] Economic burden of main Noncommunicable diseases in the Russian Federation in 2016
    Kontsevaya, A.
    Balanova, Y.
    Khudyakov, M.
    Myrzamatova, A.
    Mukaneeva, D.
    Sapunova, I.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2019, 29
  • [10] SOCIO-ECONOMIC BURDEN OF COVID-19 IN RUSSIAN FEDERATION
    Kolbin, A.
    Gomon, J.
    Balykina, Y.
    Belousov, D.
    Ivanov, I.
    [J]. VALUE IN HEALTH, 2020, 23 : S555 - S555